Welcome to our dedicated page for Serina Therapeutics SEC filings (Ticker: ser), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Serina Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Serina Therapeutics's regulatory disclosures and financial reporting.
Serina Therapeutics, Inc. reported leadership and governance updates. Its subsidiary, Serina Therapeutics (AL), Inc., promoted Srini Tenjarla, Ph.D., to Chief Technology Officer, increasing his annual base salary to $425,000, effective back to March 15, 2026. The Company also raised Chief Executive Officer Steve Ledger’s annual base salary to $500,000, effective as of September 9, 2024, and paid the retroactive amount in a lump sum in April 2026.
The Board approved amended and restated bylaws effective April 15, 2026. The bylaws add detailed provisions for appointing Co-Chairs of the Board, allowing a Chair or any Co-Chair to call special stockholder meetings and preside over Board and stockholder meetings, with each Co-Chair holding the same authority and powers, subject to coordination expectations.
Serina Therapeutics director Bailey Gregory acquired additional common stock through a share award. On March 31, 2026, Gregory received 59,667 shares of Serina Therapeutics common stock at $1.94 per share in a grant classified as a “grant, award, or other acquisition.”
According to a footnote, these shares were issued as payment of accrued dividends on the reporting individual’s Series A Convertible Preferred Stock issued on April 8, 2025. Following this transaction, Gregory directly holds 126,910 shares of Serina Therapeutics common stock.
Serina Therapeutics, Inc. director Venkatesan Jay reported an acquisition of 7,553 shares of common stock. These shares were issued at $1.94 per share as a grant classified as a “grant, award, or other acquisition.”
According to a footnote, the common shares were issued as payment of accrued dividends on the reporting individual’s A Convertible Preferred Stock issued on April 8, 2025. Following this non-cash dividend payment in stock, Jay directly holds 7,553 common shares.
Serina Therapeutics, Inc. has filed preliminary proxy materials for its virtual Annual Meeting of Stockholders to be held on June 17, 2026. The proxy seeks shareholder approval for governance and capital items, including a proposed increase in authorized common stock from 40,000,000 to 125,000,000 shares and a 2,000,000-share increase to the 2024 Equity Incentive Plan. Other proposals include director elections, approvals under NYSE American rules to permit issuance of shares upon conversion of Series A preferred stock and exercise of private placement securities, advisory say-on-pay votes, and ratification of the independent auditor. The Board recommends in favor of all proposals and has set the record date for voting. Proxy voting instructions, director biographies, executive compensation disclosures, equity award schedules, and committee charters are provided in the materials.
Serina Therapeutics, Inc. filed an Amendment No. 1 to its Annual Report for the year ended December 31, 2025 to correct the independent auditor’s consent. The original Form 10-K included an incorrect version of Exhibit 23.1, and this amendment replaces it with the correct consent from Frazier & Deeter, LLC.
The company also filed new certifications from its chief executive officer and chief financial officer, as required for amended reports. As of March 18, 2026, Serina Therapeutics had 12,314,159 shares of common stock outstanding. All other disclosures from the original Form 10-K remain unchanged and continue to speak as of the original filing date.
Serina Therapeutics, Inc. reported full-year 2025 results and highlighted progress for its neurology pipeline and financing. Grant revenue was $130,000 while operating expenses rose to $24.2 million, leading to a net loss attributable to common stockholders of $19.4 million, or $1.91 per share. Cash and cash equivalents were $3.1 million as of December 31, 2025.
In January 2026 the FDA cleared the IND for lead Parkinson’s candidate SER-252, and in February 2026 the first patient was dosed in a Phase 1b registrational trial. Serina also agreed to a private placement of common stock and pre-funded warrants of at least $15 million and up to $30 million, with 50% warrant coverage that could add up to $33.3 million upon exercise; by March 23, 2026, gross proceeds of $16.0 million had been received. In addition, the company’s at-the-market program has raised $12.9 million in gross proceeds to date.
Serina Therapeutics files its annual report detailing a clinical-stage pipeline built on its proprietary POZ polymer drug delivery platform. The company focuses on neurological diseases, especially Parkinson’s, aiming for continuous drug delivery with long-acting subcutaneous injections.
Lead candidate SER-252 (POZ-apomorphine) received FDA IND clearance in January 2026, and the first patient was dosed in a Phase 1b trial in February 2026 for advanced Parkinson’s disease. Earlier candidate SER-214 (POZ-rotigotine) completed a Phase Ia study in 19 subjects as proof of principle and is now intended for partnering.
Serina also develops POZ-lipids as alternatives to PEG-lipids for RNA lipid nanoparticle vaccines and therapeutics. In 2023, it signed a non‑exclusive license with Pfizer covering POZ technology for LNP formulations, including a $3 million upfront payment and tiered royalties between 2.75% and 3.5% on net sales. The report highlights an extensive global patent estate protecting POZ chemistries, Parkinson’s programs and POZ‑lipid applications.
Serina Therapeutics Chief Scientific Officer exercises and sells options-linked shares. On March 23, 2026, Randall Moreadith exercised stock options for 6,500 shares of common stock at an exercise price of $0.06 per share and then sold the same 6,500 shares in open-market transactions at a weighted average price of $2.8566 per share, with individual sale prices ranging from $2.68 to $3.03. This exercise-and-sell pattern represents a routine liquidity transaction rather than an open-market purchase.
Serina Therapeutics, Inc. entered into a private placement led by director Greg Bailey to raise up to $30 million through common stock and pre-funded warrants priced at $2.25 per share. The first tranche of $15 million closed around March 20, 2026, with a second tranche of up to $15 million anticipated by April 30, 2026.
Investors also receive redeemable warrants covering 50% of purchased shares at an exercise price of $5.00 per share and a four-year term, which, if fully exercised, could add up to $33.3 million in proceeds. Proceeds are intended to fund the SER‑252 Phase 1b registrational study for advanced Parkinson’s disease and related milestones. In connection with the financing, Greg Bailey will serve as Co‑Chairman of the Board, and investors gain the right to designate an additional non‑executive director once specified funding thresholds are met, while certain note funding obligations under an existing senior unsecured convertible promissory note have been removed.
Serina Therapeutics, Inc. Chief Scientific Officer Randall Moreadith exercised stock options for 39,000 shares of common stock at $0.06 per share and immediately sold all 39,000 shares at $2.50 per share in an open-market transaction.
The filing shows this was an exercise-and-sell event, with the reported common stock holdings reduced to 0 shares directly after the sale. The stock options involved were fully vested before exercise.